Biotechnology · Henderson, Nevada, United States
$5.28
-3.92% (-$0.21)2026-07-09
Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Net Income-$24.2M
EPS$-0.22
Market Cap$500.5M
Price Performance
Historical data including institutional events
Company Profile
S
Sandeep Kulkarni
CEO & Executive Director
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
- Founded
- 2022
- Employees
- 30
- Headquarters
- Henderson, Nevada, United States
- Website
- zurabio.com
Peer ComparisonRevenue ($B)
▾Loading company sections...